Leiden, The Netherlands, January 3, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square.
Ronald Loggers, CEO of ISA Pharmaceuticals, will present at Biotech Showcase™ as follows:
Date: Tuesday, January 9, 2018
Time: 9:45am (PST)
Room: Hilton / Franciscan C, Ballroom Level
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. In addition, ISA develops MyISA®, a personalized SLP® immunotherapy, targeting tumor-specific, mutation-derived neo-antigens.
For more information, please visit www.isa-pharma.com.
SLP®, AMPLIVANT® and MyISA® are registered trademarks in Europe.